You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 6, June 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Colon Cancer
 •Oncology, Other
 •Colorectal Surgery
 •Surgical Oncology
 •Surgical Physiology, Other
 •Prognosis/ Outcomes
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Combination of Microsatellite Instability and Lymphocytic Infiltrate as a Prognostic Indicator in Colon Cancer

Eugene Y. Chang, MD; Paul B. Dorsey, MS; Joseph Frankhouse, MD; Randall G. Lee, MD; Deb Walts, MSN; William Johnson, MD; George Anadiotis, DO; Nathalie Johnson, MD

Arch Surg. 2009;144(6):511-515.

Background  Microsatellite instability (MSI) is a genetic aberration associated with less aggressive tumor biology. Some tumors with MSI also have lymphocytic infiltrate (LI), which suggests a heightened immune response against the tumor.

Objective  To evaluate the combined prognostic significance of MSI and LI in a colon cancer population.

Design  Colon cancers were prospectively evaluated for MSI by assessing 11 satellite markers and were classified as MSI+ if 2 or more satellite markers displayed instability. Tumors were classified as LI+ if at least 5 lymphocytes were observed per 10 high-power fields.

Setting  Community hospital system.

Patients  Individuals undergoing definitive surgery for colon cancer.

Main Outcome Measures  Overall and disease-free survival were compared according to combined MSI and LI status.

Results  In 150 patients, tumors were classified as follows: 95 were MSI–/LI–, 9 were MSI–/LI+, 30 were MSI+/LI–, and 16 were MSI+/LI+. Median follow-up was 40.6 months. Five-year disease-free survival was 56.7% for patients with MSI–/LI– tumors and 88.9% for those with MSI+/LI+ tumors (P = .01). Patients with MSI+/LI– and MSI–/LI+ tumors had 5-year survival of 75.4% and 75.0%, respectively.

Conclusions  Patients with colon cancer and MSI–/LI– tumors have worse disease-free survival rate regardless of stage at diagnosis. Patients exhibiting both MSI+ and LI+ tumors have more favorable disease-free survival rates. Both MSI and LI show promise as a combined prognostic marker and with further study may prove to be particularly useful in selecting patients with stage II disease for adjunctive therapy.


Author Affiliations: Oregon Health and Science University, Department of Surgery (Dr Chang), and Legacy Health System (Drs Frankhouse, Lee, W. Johnson, Anadiotis, and N. Johnson, Mr Dorsey, and Ms Walts), Portland.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combination of Microsatellite Instability and Lymphocytic Infiltrate as a Prognostic Indicator for Adjuvant Therapy in Colon Cancer
Kumar et al.
Arch Surg 2009;144:835-840.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.